|
Originally published In Press as doi:10.1074/jbc.M109665200 on January 22, 2002
J. Biol. Chem., Vol. 277, Issue 14, 12182-12189, April 5, 2002
Punctin, a Novel ADAMTS-like Molecule, ADAMTSL-1, in
Extracellular Matrix*
Satoshi
Hirohata §,
Lauren W.
Wang §,
Masaru
Miyagi¶,
Lin
Yan¶,
Michael F.
Seldin ,
Douglas R.
Keene**,
John
W.
Crabb¶, and
Suneel S.
Apte  §§
From the Department of Biomedical Engineering, Lerner
Research Institute, the  Department of
Orthopaedic Surgery, Cleveland Clinic Foundation, the ¶ Department
of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic
Foundation, Cleveland, Ohio 44195, the Rowe Program in Genetics,
Departments of Biological Chemistry and Medicine, University of
California at Davis, Davis, California 956161, and the
** Shriner's Hospital for Children, Portland, Oregon
97201
Received for publication, October 5, 2001, and in revised form, January 17, 2002
 |
ABSTRACT |
Punctin (ADAMTSL-1) is a secreted
molecule resembling members of the ADAMTS family of proteases. Punctin
lacks the pro-metalloprotease and the disintegrin-like domain typical
of this family but contains other ADAMTS domains in precise order
including four thrombospondin type I repeats. Punctin is the product of
a distinct gene on human chromosome 9p21-22 and mouse chromosome 4 that
is expressed in adult skeletal muscle. His-tagged punctin expressed in
stably transfected High-FiveTM insect cells was
purified to apparent homogeneity by Ni-chromatography of conditioned
medium. The NH2 terminus is not blocked and has the
sequence EEDRD and so forth as determined by Edman degradation, demonstrating signal peptidase processing. Recombinant epitope-tagged punctin has a calculated mass of 59,991 Da but exhibits major molecular
species of 61970 ± 6 Da and 62131 ± 5 Da as measured by
liquid chromatography electrospray mass spectrometry. Punctin is
a glycoprotein based on carbohydrate staining and liquid chromatography electrospray mass spectrometry glycopeptide analysis. Glycosylation occurs at a single N-linked site as demonstrated by altered
electrophoretic migration of punctin expressed in the presence of
tunicamycin A. Punctin contains disulfide bonds based on antibody
accessibility and electrophoretic migration under reducing
versus nonreducing conditions. Rotary shadowing
demonstrates that punctin is hatchet-shaped having a globular region
attached to a short stem. In transfected COS-1 cells, punctin is
deposited in the cell substratum in a punctate fashion and is excluded
from focal contacts. Punctin is the first member of a novel family of
ADAMTS-like proteins that may have important functions in the
extracellular matrix.
 |
INTRODUCTION |
Metalloproteases responsible for extracellular
(ECM)1 turnover have a
modular structure. Matrix metalloproteinases (MMPs) (1), a
disintegrin-like and
metalloprotease (ADAMs) (2), and proteases of the ADAMTS
family (3, 4) are composed of characteristic domains arranged in a
precise order that is the hallmark of each family. These enzymes are
structurally and functionally bipartite consisting of an enzymatic
domain attached to nonenzymatic or ancillary domains. The ancillary
domains localize these proteases to substrates, the cell surface, or to
the ECM. The ancillary domains of the gelatinases MMP-2 and MMP-9 are
among the best studied of the substrate-binding domains. The
fibronectin type II domains of the gelatinases are involved in binding
to gelatin and some collagens as well as to fibronectin and heparin as
in the case of MMP-2 (5, 6). The gelatin-binding domain of MMP-2 binds
the matricellular proteins thrombospondin-1 (TSP1) and TSP2 (7).
Although neither is a substrate for MMP-2, the interaction may mediate
the clearance of MMP-2 and affect cell-adhesive properties (8). The
MMP-2 hemopexin domain interacts with the carboxyl terminus of the
tissue inhibitor of metalloproteases-2, facilitating pro-MMP-2
activation by membrane-type MMPs (1, 5, 6, 9). The MMP-2 hemopexin
domain also interacts with a chemokine called monocyte chemoattractant
protein-3, which allows its processing by the catalytic domain (10).
The disintegrin domains of ADAMs such as ADAM-15 are implicated in
cell-cell adhesion (2, 11, 12), and the ancillary domains of ADAMTS-1
are required for its binding to the ECM (13). In some ADAMs, the zinc-binding active site is nonfunctional, suggesting that they do not
function as proteases at all but may instead have a primary role in
adhesion via their ancillary domains (2).
With this background, it is conceptually possible that gene products
containing only the ancillary domains of ADAMTS may have specific
functions in cell-cell or cell-matrix interactions or may regulate
ADAMTS proteases. We have identified an ADAMTS-like (ADAMTSL) molecule
named punctin,2 which is the
product of a gene distinct from any in the ADAMTS family and is
composed of ADAMTS ancillary domains alone. We have purified and
characterized recombinant punctin produced in insect cells, visualized
it by electron microscopy, and demonstrated that it is a glycoprotein
and a component of the ECM.
 |
EXPERIMENTAL PROCEDURES |
cDNA Cloning and Sequence Analysis--
Using BLAST programs
from the National Center for Biotechnology Information, we scanned the
data base of ESTs using the protein sequences of ADAMTS proteases
previously cloned by us (4, 14) and identified a human EST
(GenBankTM accession number AA482392 encoded by IMAGE clone
752797). The EST predicted a polypeptide with a similarity to the
carboxyl half of cognate ADAMTS members but with no identities in
GenBankTM or other protein and nucleotide data bases.
Using nested oligonucleotide primers based on the sequences at the 5'
and 3' ends of the IMAGE clone insert and human skeletal muscle
cDNA (Marathon cDNA, CLONTECH, Palo Alto,
CA) as the template, we performed RACE and extended the cDNA at 5'
and 3' ends by PCR essentially as described previously (4, 14).
Northern Blot Analysis--
Multiple tissue Northern blots from
adult human and mouse tissues (CLONTECH, Palo Alto,
CA) were hybridized to a [ -32P]dCTP-labeled punctin
probe, a 1200-bp cDNA fragment from the 5' end of the
punctin coding sequence, followed by autoradiographic exposure for 7 days.
Chromosomal Mapping and Genomic Arrangement--
To determine
the chromosomal location of Adamtsl1, we analyzed
a panel of DNA samples from an interspecific cross that has been
characterized for over 1200 genetic markers throughout the mouse genome
(15). Markers can be seen on the worldwide web
(www.informatics.jax.org/searches/crossdata_form.shtml) by entering
"DNA Mapping Panel Data Sets" from the mouse genome data base and
then selecting the "Seldin cross" and "Chromosome."
Initially, DNA from the two parental mice, (C3H/HeJ-gld) and
(C3H/HeJ-gld × Mus spretus)
F1), were digested with various restriction
endonucleases and hybridized with the Adamtsl1 cDNA
probe (IMAGE clone 2076907 with GenBankTM accession number
AI787975) to determine restriction fragment length variants for
haplotype analyses. Gene linkage was determined by segregation
analysis. Gene order was determined by analyzing all haplotypes and
minimizing crossover frequency among all genes that were determined to
be within a linkage group. This method resulted in the determination of
the most probable gene order. To define the locus for
ADAMTSL1, the human punctin cDNA sequence was used for
BLAST searches of the human genome (Celera Sciences, Rockville, MD).
Generation and Characterization of Anti-punctin
Antisera--
The peptide
(NH2)-[C]YYPENIKPKPKLQE-(OH) located in the third
TS domain of punctin (Fig. 1B) was synthesized using Fmoc
(N-(9-fluorenyl)methoxycarbonyl) chemistry, purified by
reverse-phase high-pressure liquid chromatography, and molecular weight
was confirmed by MS (Alpha Diagnostic International, San Antonio, TX).
A cysteine ([C]) residue was included at the NH2 terminus
for coupling to keyhole limpet hemocyanin. Peptide-keyhole limpet
hemocyanin conjugate was dialyzed in PBS and used for immunization. Two
New Zealand White male rabbits (7-8 pounds) were immunized with the
conjugate (~200 µg/injection/rabbit, multiple intramuscular and
subcutaneous sites) at biweekly intervals for 8 weeks. After an initial
injection in Freund's complete adjuvant, subsequent injections were
given in incomplete adjuvant. Antibody titer was measured by
enzyme-linked immunosorbent assay using free peptide.
Immune sera were tested by Western blot analysis of extracts from COS-1
cells transiently transfected with punctin cDNA (see below).
Although antisera from both rabbits (antisera 4112 and 4113) gave
qualitatively similar results, the best signal/noise ratio was obtained
with antiserum 4113. Affinity-purified antibodies were prepared by
column chromatography of antiserum 4113 using the immobilized peptide immunogen.
Expression and Purification of Recombinant Punctin from Insect
Cells--
High-FiveTM cells (Invitrogen) were routinely
cultured on tissue culture plastic and maintained at 27 °C in
UltimateTM serum-free insect cell medium (Invitrogen) as
per manufacturer's directions. The full-length punctin ORF was excised
from pcDNA3.1/Myc-His B-TSL1 (see below) with EcoRI and
NotI and ligated into the corresponding sites in pIZT/V5-His
(Invitrogen). The resulting insect cell expression plasmid
pIZT/V5-His-TSL1 generated punctin with a COOH-terminal V5 epitope and
6× His tag. pIZT/V5-His-TSL1 was transfected into High-FiveTM cells using Insectin-Plus liposomes
(Invitrogen) and plated onto 100-mm Petri dishes. After 48 h,
antibiotic selection (500 µg/ml Zeocin, Invitrogen) was
started and continued for 21 days. Colonies that survived selection
were picked manually, expanded, and maintained in medium containing
Zeocin (50 µg/ml). Punctin production by isolated colonies was tested
by Western blot analysis of conditioned medium using anti-His
monoclonal antibody (Invitrogen) and antibody 4113.
For protein production, cells were grown in suspension in either
UltimateTM serum-free insect cell medium or Express-Five
serum-free medium containing heparin (5 units/ml,
Invitrogen). Production cultures were in spinner flasks, and
culture medium was stored at 80 °C with 1 mM
phenylmethylsulfonyl fluoride until use. For purification, medium was
dialyzed into binding buffer (20 mM sodium phosphate, 500 mM NaCl, pH 7.8) containing 0.03% Brij-35 (Sigma).
Purification was performed using 1-liter batches of dialyzed
medium and a 5-ml Ni-Sepharose column (ProBondTM,
Invitrogen) on an fast protein liquid chromatography instrument (Bio-Rad, Hercules, CA). Following binding, the column was washed with
three column volumes of binding buffer. A gradient of 0-42.5 mM imidazole in binding buffer was used to remove
nonspecifically bound molecules from the column. Elution was with four
column volumes of 250 mM imidazole in binding buffer, pH
7.0, containing 0.03% Brij-35. Elution was monitored by in-line UV and
conductivity measurements. 2-ml fractions of eluate were collected and
tested by Western blot analysis as described above. Fractions
containing punctin were pooled. Protein concentration was determined
using the Bradford assay (Bio-Rad) and by phenylthiocarbamyl amino acid analysis using an Applied Biosystems model 420H/130/920 automated analysis system (16).
Characterization of Recombinant Punctin--
The
NH2-terminal sequence of recombinant punctin was determined
by Edman degradation. Recombinant punctin (5 µg) was electrophoresed on 10% SDS-PAGE, electrotransferred to polyvinylidene difluoride membrane, and lightly stained with modified Coomassie Blue (Simply Blue
Safe Stain, Invitrogen). Protein bands were excised and subjected to
Edman degradation on an Applied Biosystems Procise 492 sequencer in the
Molecular Biotechnology Core Facility of the Lerner Research Institute.
To probe for glycosylation, recombinant punctin (4 µg) was
electrophoresed on 10% SDS-PAGE and stained for carbohydrate using a
periodic acid-Schiff reaction-based method (Pro-Q fuchsia glycoprotein staining kit, Molecular Probes, Eugene, OR). In this reaction, CandyCaneTM glycoprotein molecular weight standards
consisting of alternate bands of glycosylated and unglycosylated
proteins were used as controls. Glycoprotein staining was also
performed after enzymatic deglycosylation of punctin with peptide
N-glycosidase F. Deglycosylation of denatured as well as
native punctin was performed with a commercially available kit
(Bio-Rad) using bovine fetuin as a control. To investigate further whether N-linked carbohydrates were present in
punctin, stably transfected insect cells were cultured in the presence or absence of tunicamycin A1 homolog (0.1 µg/ml culture medium, Sigma). Equal amounts of total protein from culture medium of tunicamycin-treated and untreated cells were assayed by Western blot
with antibody 4113 at various time points after the addition of
tunicamycin
Mass Spectrometry--
The molecular mass of punctin was
measured by MALDI-TOF and by LC-ESMS. MALDI-TOF was performed with a
PerkinElmer Biosystems Voyager DE Pro-mass spectrometer using sinapinic
acid as the matrix and bovine serum albumin as a calibration standard
protein (17). MALDI-TOF MS measurements of intact punctin and naturally
observed limited proteolysis fragments are reported ± 50% peak
width (in Da) at half-maximal peak height. LC-ESMS was performed with a PerkinElmer Sciex API 3000 triple quadruple mass spectrometer (17, 18).
Nitrogen was used as the nebulization gas at 40 p.s.i., and
curtain gas was supplied from a nitrogen generator (Whatman model
75-72). For LC-ESMS of intact punctin, a scan range of 700-1800
m/z was used with 0.2 atomic mass unit steps, a
scan time of 7.5 s, and at an orifice potential of 80 and 5000 V
ion spray. Reverse phase-high-pressure liquid chromatography was done at a flow rate of 5 µl/min on a 5-µm Vydac C18 capillary column (0.3 × 150 mm, LC Packing) using an Applied Biosystems Model 140D high-pressure liquid chromatography system and aqueous
acetonitrile/trifluoroacetic acid solvents with 100% of the eluant
going to the mass spectrometer. ESMS measurements of intact
punctin are reported as the mean ± S.E. (in Da).
For glycopeptide characterization, punctin was excised from a
SDS-polyacrylamide gel (~1 µg/lane × 6 lanes), in-gel reduced with 10 mM dithiothreitol, cysteine-alkylated with 20 mM iodoacetamide in 400 mM ammonium
bicarbonate, and digested with 0.2 µg of trypsin (Promega) overnight
at 37 °C in 100 mM ammonium bicarbonate. Peptides from
the in-gel tryptic digests were extracted with 60% acetonitrile containing 0.1% trifluoroacetic acid, dried in a Speed Vac,
redissolved in 50 µl of 0.1% trifluoroacetic acid, and analyzed by
LC-ESMS using selective ion monitoring with the PE Sciex API 3000 triple quadruple mass spectrometer system as described above for intact protein analyses. Glycopeptides were selectively detected based on
diagnostic sugar oxonium ions HexNAc + Hex (m/z
366) and N-acetylneuraminic acid (NeuAc)
(m/z 292) (17). Carbohydrate marker ions at
m/z 366 and 292 (dwell time 200 ms each) were
monitored in a positive ion mode at a high orifice potential (180 V),
whereas full scans at m/z 300-2300 (0.2 atomic
mass unit steps, scan time 3.5 s) were acquired at a lower orifice
potential (70 V). This way both intact parent ions and abundant marker
ions were observed in the same m/z scan.
Rotary Shadowing and Electron Microscopy of Recombinant
Punctin--
Rotary shadowing was done essentially as described
previously (19). A 30-µl sample of punctin at 100 µg/ml was mixed
with 70 µl of glycerol and nebulized onto freshly cleaved mica using an airbrush. The sample was dried in a vacuum, and rotary shadowed using a platinum-carbon electron beam gun angled at 6° relative to
the mica surface within a Balzers BAE 250 evaporator. The replica was
backed with carbon, floated onto distilled water, and picked up onto
600 mesh grids. Photomicrographs were taken using a Philips 410 electron microscope operated at 80 kV.
Transient Expression of Tagged and Untagged Punctin in COS-1
Cells--
An internal SacI site and a flanking
NotI site were used to remove a 1.5-kb fragment of IMAGE
clone 752797 and ligate it into corresponding sites in IMAGE clone
2150669 corresponding to the 5' end of the punctin cDNA to generate
a complete ORF. EcoRI and NotI sites flanking
this ORF were used to excise and clone the full-length coding sequence
into pcDNA3.1/Myc-His (+) A (Invitrogen) for the expression of
untagged punctin. To make constructs in which the ADAMTSL1
ORF was in-frame with a carboxyl-terminal FLAG tag or a tandem
myc tag and 6× His tag, PCR was performed with Advantage 2 polymerase (CLONTECH, Palo Alto, CA) using the
full-length coding sequence as a template. The amplicons were cloned
into the vectors pFLAG-CMV5c (Sigma) and pcDNA3.1/Myc-His B
(Invitrogen) for expression with either a COOH-terminal FLAG tag or a
COOH-terminal tandem myc tag and 6× His tag, respectively.
COS-1 cells (ATCC number CRL-1650) were grown on tissue culture plastic
in Dulbecco's modified Eagle's medium:F-12 (1:1) (Lerner Research
Institute Media Services) supplemented with 10% fetal bovine serum
(Invitrogen) and antibiotics (100 units/ml of penicillin and 50 µg/ml
streptomycin). 105 cells between passages 3 and 10 were
transfected with untagged, FLAG-tagged, or myc + 6×
His-tagged punctin using FuGENE 6 (Roche Molecular Biochemicals) as per
manufacturer's recommendations, and cells were grown for an additional
24-48 h in serum-supplemented or serum-free medium. As a control,
cells were transfected with the respective vector alone without insert.
The medium was collected and concentrated 10-fold. Cells were harvested
after detachment with 10 mM EDTA for 10-15 min at
37 °C. A complete detachment of cells was confirmed by
phase-contrast microscopy. Fifty microliters of 2× Laemmli sample
buffer was added to the wells, and the ECM was scraped off. Samples of
cell lysate, medium, and ECM were separately electrophoresed under
reducing conditions (samples were boiled following the addition of 10%
(v/v) 2-mercaptoethanol) on 12% SDS-polyacrylamide gels and
transferred to enhanced chemiluminescence (ECL)-Hybond (Amersham
Biosciences, Inc.). Western blotting was performed using either
anti-FLAG M2 antibody (diluted 1:500, Sigma), anti-His (COOH-terminal)
antibody (diluted 1:1000, Invitrogen) or antibody 4113 (diluted 1:300)
depending on the construct used for transfection. Antibody binding was
detected using the appropriate peroxidase-labeled second antibody
followed by ECL using reagents from Amersham Biosciences, Inc.
For immunocytochemistry, COS-1 cells were grown on glass coverslips in
35-mm diameter wells (in 6-well plates) and transiently transfected as
described above in serum-supplemented or serum-free medium. The medium
was removed 48 h after transfections. The cells were washed three
times on ice with cold PBS containing 1 mM
CaCl2 and 1 mM MgCl2 and incubated
for 1 h on ice with 1 ml of culture medium containing anti-FLAG M2
monoclonal antibody (diluted 1:300, Sigma) or anti-punctin rabbit
antisera (diluted 1:100) with gentle shaking. Cells were washed
four times for 3 min each with cold PBS, fixed in 4% paraformaldehyde
(w/v in PBS) (Sigma) on ice for 30 min with gentle shaking and then
washed three times with PBS at ambient temperature. To quench free
aldehyde groups, cells were treated with 75 mM ammonium
chloride, 20 mM glycine for 10 min at ambient temperature,
washed with PBS, and then blocked with 0.05% Triton X-100, 2% normal
goat serum in PBS (10 min at ambient temperature). Finally, sections
were incubated with the species-appropriate Texas Red-labeled goat
secondary antibody (Jackson ImmunoResearch Laboratories, West Grove,
PA) prior to coverslip mounting in Vectashield containing
4',6-diamidino-2-phenylindole (Vector Laboratories, Inc., Burlingame,
CA). The following control-immunostaining experiments were performed.
COS-1 cells transfected with the vector alone or untransfected COS-1
cells were stained with the above antibodies, or transfected cells were
stained with preimmune serum from the rabbits in which the polyclonal
antibodies were produced.
To co-stain punctin and the actin cytoskeleton, cells were stained with
anti-FLAG or anti-punctin antibodies as described above with the
exception that the secondary antibodies included incubation with Alexa
488-phalloidin at recommended dilutions (Molecular Probes). In double
immunostaining experiments following the immunolocalization of FLAG or
punctin as described above, cells were permeabilized with 0.1% Triton
X-100 in PBS for 20 min prior to staining with (a)
monoclonal antibody to vinculin (1:100 dilution, Sigma) in
combination with antiserum 4113 for the detection of punctin or
(b) polyclonal antibody to focal adhesion kinase (1:200
dilution, Upstate Biotechnology, Lake Placid, NY) in combination with
anti-FLAG monoclonal antibody M2 (Sigma) for the detection of punctin.
A Texas Red-labeled antibody (Jackson ImmunoResearch Laboratories) was
used for the detection of punctin, and Alexa 488-conjugated antibody
(Molecular Probes) was used for the detection of vinculin or focal
adhesion kinase.
 |
RESULTS |
Cloning of Punctin cDNA--
We identified a novel EST
(GenBankTM accession number AA482392) derived from pooled
human melanocyte, fetal heart, and pregnant uterus with homology to
ADAMTS proteases. The 1.5-kb insert of the corresponding IMAGE clone
752797 contained a long ORF encoding an amino-terminal TS domain, a
cysteine-rich domain, a cysteine-free spacer domain, and three tandem
TS modules followed by a short acidic peptide and stop codon (Fig.
1a). The stop codon and
3'-untranslated sequence were independently confirmed by 3'-RACE (clone
pSHTSL1s3, Fig. 1a) as well as by another EST
(GenBankTM accession number W47029). The 3'-untranslated
region encoded in IMAGE clone 752797 contained a consensus
polyadenylation signal (AATTAAA) followed by a poly(A) tail 14 nucleotides downstream. Completion of the full-length coding sequences
by 5'-RACE predicted a putative signal peptide upstream of the central
TS domain. The signal peptide was preceded by a methionine codon within
a satisfactory Kozak consensus sequence (A at 3, G at +4 relative to
ATG) (20) although there was no upstream in-frame stop codon. The 5'
sequence obtained by RACE was subsequently validated by independently
cloned human and mouse ESTs (GenbankTM accession numbers
A1459225 for human EST and AK020115 for mouse EST). The continuity of
the cDNA clones was confirmed by PCR amplification of the
full-length punctin ORF from human skeletal muscle cDNA (see below)
as well as by identification of the encoding exons arranged
sequentially on human chromosome 9 (Celera Genomics, Rockville,
MD).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 1.
a, domain organization of
punctin/ADAMTSL-1 shown relative to ADAMTS-1, the prototypic ADAMTS.
The cloning strategy used for determination of the complete primary
structure is shown. The location of each cDNA clone relative to the
protein domains indicates the regions it encodes. The key to the
domains is shown at the bottom of the figure. b,
the predicted amino acid sequence of punctin is shown using the
single-letter amino acid code. TS modules are underlined
with the thick line and are numbered sequentially from amino
to carboxyl terminus. A consensus sequence for
N-linked glycosylation is overlined. Cysteine
residues are indicated by asterisks. The start of the spacer
domain is indicated, the region between the NH2-terminal TS
domain and the spacer domain is the cysteine-rich domain. The
dashed line indicates the peptide used for the generation of
antibodies. The arrow indicates the signal peptidase
cleavage site. The arrowhead indicates a putative
proteolytic processing site between TS domains 2 and 3. c,
segregation of Adamtsl1 on mouse chromosome 4 in
((C3H/HeJ-gld × M. spretus) F1 × C3H/HeJ-gld) interspecific backcross mice. Filled
boxes represent the homozygous C3H pattern, and open
boxes represent the Fl pattern. The mapping of the
reference loci in this interspecific cross has been previously
described (15).
|
|
Primary Structure of Punctin Predicts an ADAMTS-like
Protein--
The predicted full-length punctin protein contains 525 amino acids and has the typical domain structure of the ancillary
noncatalytic regions of an ADAMTS protease (Fig. 1a). The
mature secreted form of punctin is 497 amino acids with a molecular
mass of 55,240 Da and a calculated pI of 6.2. Like the ADAMTS
proteases, each domain in punctin has an even number of cysteine
residues. This observation suggests that each domain may have internal
disulfide bonds (17 such bonds are predicted in punctin), and that
punctin consists of a series of independently-folded and
disulfide-bonded domains. Punctin contains no other domains apart from
those described previously in the ADAMTS family. The punctin sequence
contains one motif for N-linked glycosylation (21) at
Asn223 (-Asn-X-Ser/Thr-, where
X is any amino acid except Pro) and also contains a total of
75 Thr and Ser residues, where O-linked glycosylation might
occur. (Fig. 1b).
The overall punctin sequence is most similar to human ADAMTSL-3 (68%
identity, see below). Of the ADAMTS enzymes published to date,
punctin is most similar to human ADAMTS-10 (35% identity). The
punctin TS domains have a higher degree of similarity to other ADAMTS-like proteins and ADAMTS proteases than to TSP1 and TSP2. The
greatest similarities, as indicated by percentage of identity of amino
acid sequences identified by BLAST searches of the first TS domain of
punctin to TS domains from various molecules, are as follows: human
ADAMTSL-3, 80%; human ADAMTS-1, ADAMTS-6, and ADAMTS-10, 50%; mouse
papilin, 47%; human ADAMTS-8, 44%; human ADAMTS-5, 42%; human
TSP2, 40%; human TSP1, 38%. Like most TS domains in the ADAMTS
family, punctin TS domains do not contain linear peptide sequences
found in TSP1 that have been defined as heparin or CD-36 binding
sequences, (22). They do not contain degenerate GAG binding sequences
such as BBXB, where B is the basic amino acid and
X is any amino acid (22).
Genomic Location of the Mouse and Human Punctin Genes and
Tissue-specific Expression--
The mapping of Adamtsl1 in
an interspecific cross resulted in the following most probable gene
order (mean ± S.D.): Ptprd-4.4 ± 2.0 centimorgan-Adamtsl1, Cdkn2a-1.8 ± 1.2 centimorgan-Jun and placed Adamtsl1 at a
consensus position of 42.6 centimorgan on mouse chromosome 4 (Fig.
1c) in the vicinity of the interferon gene cluster. A search
of the mouse genome data base (www.informatics.jax.org) did not reveal
any pertinent genetic disorders near this locus.
The human-mouse homology maps (www3.ncbi.nlm.nih.gov/Omim/Homology/,
accessed September 26, 2001) predict that the ADAMTSL1 locus
is on human chromosome 9p21-22. The predicted locus was confirmed by
the analysis of the human genome sequence. The punctin ORF is encoded
by 13 exons spanning >250 kb of genomic DNA mapping to
9p21.2-22.1. A search of the Online Mendelian Inheritance in Man
site (www3.ncbi.nlm.nih.gov/Omim/) revealed three unsolved human
disorders in the vicinity of the ADAMTSL1 locus. Diaphyseal medullary stenosis with malignant fibrous histiocytoma
(MIM112250) is linked to 9p22-p21, Friedreich's ataxia 2 (MIM601992) is linked to 9p23-p11, and neuropathy, distal hereditary
motor, Jerash type (MIM605726) are linked to 9p21.1-p12.
ADAMTSL1 is primarily expressed in human and mouse skeletal
muscle with a major message size of ~7.0 kb in both species (Fig. 2). A minor messenger RNA species of
~1.0 kb was also seen in some human tissues (Fig. 2, skeletal muscle,
heart, colon, kidney, and liver). Expression was not detected in brain,
colon, thymus, spleen, placenta, small intestine, lung, testis, ovary,
or peripheral blood leukocytes.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 2.
Northern analysis of expression of
ADAMTSL1 (left) and
Adamtsl1 (right) in adult human and
mouse tissues, respectively. Kilobase markers of RNA are shown at
the left of each autoradiogram, and tissue origin is
indicated above each lane. Hybridizing transcripts are indicated by
arrows.
|
|
Expression and Characterization of Recombinant
Punctin--
Punctin expressed in High-FiveTM cells with
tandem COOH-terminal V5 and 6× His epitopes was secreted into the
conditioned medium of adherent as well as suspension cultures. Punctin
was detected by antibody 4113 and anti-epitope tag antibodies as a
~60-kDa band under reducing conditions. It was substantially purified from the culture medium using Ni-chromatography (Fig.
3a). The purification scheme
yielded a maximum of 200 µg/liter purified protein as determined by
amino acid analysis. Electrophoresis and Western blotting of
concentrated punctin preparations frequently demonstrated additional
bands of molecular mass (~120 and ~180 kDa, data not shown),
suggesting the formation of dimers and trimers at high
concentrations.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 3.
Analysis of epitope-tagged punctin purified
by Ni-chromatography from insect cell culture medium.
a, Coomassie Blue (Simply Blue Safe Stain) staining of
purified recombinant punctin on reducing SDS-PAGE (left
lane) and Western blot analysis with anti-punctin antibody 4113 (right lane). b, Western blot analysis using
anti-His tag monoclonal antibody on reducing (left lane) and
nonreducing SDS-PAGE (right lane). c,
glycoprotein staining of recombinant punctin (lane 2 contains 0.6 µg, and lane 3 contains 3 µg) using the
periodic acid-Schiff procedure. Glycosylated CandyCaneTM
markers (1 µg/band) stained similarly are in lane 1. The
arrow indicates stained punctin. d, Western
analysis of culture medium from insect cell cultures treated without
(left lane) or with (right lane) tunicamycin A
for 72 h. Each lane contains 2.8 µg of total protein.
Double arrowheads are used to indicate two molecular species
seen on Western blots.
|
|
The conformation of punctin appears to be maintained by disulfide bonds
as evidenced by more rapid migration in SDS-PAGE under nonreducing
conditions than under reducing conditions (Fig. 3b). Furthermore, on Western blots under nonreducing conditions, the protein
was not detectable with antibody 4113 (data not shown), suggesting that
the peptide epitope was not accessible without reduction of disulfide
bonds. A mass analysis of His-tagged punctin by MALDI-TOF MS yielded a
broad peak suggesting that the 60-kDa gel band contained major
molecular species of 61,935 ± 595 and 60,873 ± 295 Da,
respectively. LC-ESMS analyses of the intact protein defined more
precisely the major molecular species to be 61,970 ± 6 and
62,131 ± 5, which are, respectively, 1979 and 2140 Da larger than
the calculated mass (59,991) of tagged punctin based on amino acid
sequence. NH2-terminal sequencing of the polyvinylidene difluoride-immobilized 60-kDa protein revealed a single sequence, which
commenced at Glu29 (i.e.
Glu-Glu-Asp-Arg-Asp-Gly and so on).
Recombinant Punctin Is Glycosylated--
Two closely spaced
punctin bands were resolved by Western blot analysis of conditioned
medium or purified protein, although Coomassie Blue staining of
purified punctin always demonstrated a single band (Fig.
3a). A periodic acid-Schiff-based method of staining
carbohydrate chains suggested that recombinant punctin is a
glycoprotein (Fig. 3c), and mass spectrometry demonstrated multiple molecular species consistent with variable glycosylation. Treatment of recombinant protein with peptide N-glycosidase
F did not result in a perceptible decrease in molecular mass, although the intensity of glycoprotein staining was decreased (data not shown).
Culture medium from tunicamycin-treated cells exhibited only a single
punctin species as demonstrated by Western blotting (Fig.
3d). The difference (161 Da) between the LC-ESMS-observed masses of the major punctin molecular species (61,970 and 62,131 Da) is
close to the in-chain chemical average mass of a oligosaccharide residue (Hex, 162). Minor molecular species were also apparent by
LC-ESMS analysis, which differed by mass increments that approximated the in-chain chemical average mass of oligosaccharide residues (e.g. Hex, 162; HexNAc, 203; NeuAc, 291). For a further
analysis, tryptic digests of the protein were examined by analytical
LC-ESMS using stepped collision energy scanning to produce
carbohydrate-specific marker ions. Glycopeptides were detected
including molecular species with masses of 5881.4 ± 0.4 and
6171.2 ± 0.2 Da. The mass difference (289.8 Da) between these
observed glycopeptides appears to correspond to the in-chain chemical
average mass of N-acetylneuraminic acid (NeuAc, 291).
Taken together, these data indicated that punctin is glycosylated,
although specific glycopeptides have yet to be characterized fully.
Approximately 65% of the amino acid sequence in punctin was identified
by peptide mass mapping including the NH2-terminal tryptic
peptide (Glu29-Arg47), verifying that
the target protein has been expressed. Based on the difference between
the observed and calculated masses of intact punctin, the recombinant
protein contains approximately 3-4% carbohydrate by weight.
During purification of punctin in the absence of protease inhibitors,
additional components of ~40 and 20 kDa, respectively, were detected
on Coomassie Blue-stained gels (data not shown). The 40-kDa band
contained two molecular species with measured masses of 38,409 ± 115 and 39,456 ± 156 Da, respectively, as determined by MALDI-TOF
MS. The NH2-terminal sequencing of these bands yielded the
same amino terminus as the full-length punctin. The ~20-kDa fragment
exhibited an NH2-terminal sequence
372DLYHPL, indicating that the fragment is from the
carboxyl terminus. The addition of 1 mM
phenylmethylsulfonyl fluoride to culture medium effectively prevented
this proteolysis, suggesting that it was effected by a serine protease.
Visualization of Punctin by Rotary Shadowing--
Rotary shadowing
of purified recombinant punctin demonstrated a hatchet-shaped or
comma-shaped molecule 30-40 µm in length (Fig.
4). Punctin consists of a single globular
domain of 10-20 µm in size with a short linear segment at one end.
Most of the visualized protein was in monomeric form (Fig. 4).
Occasional aggregates with the appearance of dimers and trimers were
seen but have not yet been resolved in detail.

View larger version (207K):
[in this window]
[in a new window]
|
Fig. 4.
Rotary shadowing of recombinant punctin.
a, overview. b-g, images of individual punctin
molecules. Scale bar in panel a indicates
molecular dimensions in all panels.
|
|
Expression and Localization of Punctin in Transfected COS-1
Cells--
Transfected cells were stained without fixation or
permeabilization and on ice (live staining) to prevent the detection of intracellular punctin or endocytosed antibody, respectively. Under these conditions, punctin was localized underneath the cells
(i.e. adjacent to their ventral surface) in the substratum
laid down on plastic. The staining pattern was punctate (Fig.
5, a-d) and was
preferentially located toward the periphery of the cells (Fig. 5,
a, b, and d) and under cellular processes (Fig.
5c). The punctin deposits were of submicron dimension,
although fluorescent signals from closely located deposits were
frequently merged suggesting larger aggregates. Transfected cells had
minimal or no staining on the dorsal cell surface. Punctin was not seen
in the substratum in areas not corresponding to the cells. If
cells were detached with 10 mM EDTA prior to staining,
"footprints" of transfected cells were retained on the substratum
with a similar staining pattern as under intact cells. Staining was
seen in some areas not covered with cell processes. In other areas,
there were cell processes without underlying punctin (Fig.
5c). We interpret this finding to result from cellular
motility (i.e. withdrawal of existing processes and the
formation of new ones). Identical results were obtained with anti-FLAG
monoclonal antibody or antibody 4113. Fig. 5, a-c, shows
staining of FLAG-tagged protein using the FLAG M2 monoclonal antibody,
and Fig. 5d shows staining with anti-punctin antiserum 4113. Similar staining patterns were seen whether cells were grown in the
presence or absence of serum and using tagged or untagged proteins
(data not shown).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 5.
a-d, confocal laser-scanning
microscopy of COS-1 cells following transient transfection with
ADAMTSL1 expression constructs and immunocytochemistry.
Untransfected cells are visible in a and b. Scale
bar (10 µm) is shown at lower right of each panel.
a and b, punctate staining of FLAG-tagged punctin
(red) in nonpermeabilized cells visualized with anti-FLAG M2
antibody. Nuclei are blue 4',6-diamidino-2-phenylindole.
c, relationship of punctin staining (red)
visualized with anti-FLAG M2 monoclonal antibody to cellular actin as
visualized by phalloidin staining (green). The
asterisk indicates a cellular protrusion that does not have
underlying punctin, and the arrow indicates punctin
immunolocalization without an overlying cellular process. d,
relationship of punctin (red) visualized with anti-punctin
antiserum 4113 to vinculin staining (green) as shown by
confocal imaging and overlay of single-color images from a
double-stained cell. e, Western blot analysis of cell
lysates (lane 1), medium (lane 2), and ECM
(lane 3) from transfected COS-1 cells using an anti-His tag
monoclonal antibody. Cell lysates from untransfected COS-1 cells are
shown in lane 4. Molecular mass is indicated on the
left.
|
|
Double staining for vinculin (Fig. 5d) or focal adhesion
kinase (data not shown), components of focal contacts, indicated that
punctin staining did not correspond to sites of focal contacts. No
staining was visible in control experiments, i.e. in
untransfected COS cells, cells transfected with vector alone, cells
stained without a primary antibody, or cells stained with preimmune
serum as control.
On Western blots, we found reactive protein bands of the expected size
(58-60 kDa for untagged punctin and 62-64 kDa for the His-tagged or
FLAG-tagged forms) in the medium, cell layer, and the underlying
substratum or ECM of transfected COS-1 cells (Fig. 5e). In
contrast, cells transfected with vector alone (Fig. 5e) or
untransfected cells (data not shown) did not show a reactive band. As
controls, preimmune serum from the rabbits in which anti-Punctin antibodies were generated did not produce immunoreactivity on Western
blots (data not shown).
 |
DISCUSSION |
Punctin/ADAMTSL-1 Is a Novel ADAMTS-like Secreted Protein Belonging
to a Distinct ADAMTSL Family of Proteins--
In addition to missing
the catalytic domain, the ADAMTS-like proteins (see below) do not
possess disintegrin-like domains. This finding suggests that the
disintegrin-like domain and catalytic domain may represent a
functionally coupled protease domain in ADAMTS enzymes. Further
evidence for this comes from the identification of other proteins with
a predicted structure similar to punctin. Following the complete
cloning of punctin/ADAMTSL-1, we became aware of a second such molecule
encoded by the KIAA0605 gene (GenBankTM
accession number AB011177) that we designated as ADAMTSL-2 (23). We
have cloned a third ADAMTS-like protein, ADAMTSL-3 (GenBankTM accession number
AF237652).3
Therefore, punctin belongs to a distinct protein family. ADAMTSL-2 and
ADAMTSL-3 differ from punctin in their greater length (951 and 1690 amino acids, respectively) and also have more TS domains (6 and 10, respectively). These molecules will be described in greater detail in
subsequent publications. In contrast to ADAMTSL-2 and ADAMTSL-3, which
are quite widely expressed,4
punctin/ADAMTSL-1 is selectively expressed in muscle.
Other secreted ECM molecules such as lacunin and papilin also contain
the ancillary domains of the ADAMTS family in the precise order as
punctin. However, punctin is more closely related to ADAMTSL-3 and some
ADAMTS proteases than it is to mouse papilin (32% identity). Lacunin
is a basement membrane glycoprotein in the moth Manduca
sexta (24). Lacunin has the structure of ADAMTSL including seven
TS modules as well as a single COOH-terminal protease and lacunin
domain. In addition, it contains 13 repeats of a novel lagrin domain,
11 Kunitz inhibitor domains, 2 antistasin-like domains, 1 serine
protease inhibitor domain, and 2 immunoglobulin domains. Lacunin
localizes to the basal lamina of the moth wing (24). Papilin from
Drosophila melanogaster may be an ortholog of M. sexta lacunin, because the two molecules are similar in their
domain content, organization, and primary sequence. Papilin is also a
basement membrane protein (25). Although these invertebrate proteins
have numerous protease inhibitor domains, mammalian papilin contains
substantially fewer such domains (25).
Characterization of Recombinant Punctin from Insect Cells--
Our
experimental data support the likelihood that recombinant punctin is
disulfide-bonded. First, its electrophoretic mobility is greater under
nonreducing conditions. Second, the punctin epitope is masked under
nonreducing conditions. Third, rotary shadowing demonstrated a molecule
with a specific and consistent conformation. Limited proteolysis within
the linker peptide, connecting TS domains 2 and 3 assigned to the
Tyr371-Asp372 peptide bond (Fig. 1b)
by a putative serine protease, indicates that there may be a
proteolytically susceptible exposed region between the two
disulfide-bonded TS domains. It is not yet known whether this is a
physiologically relevant processing or whether it is an artifact that
is unique to this expression system. The processing event releases the
two COOH-terminal TS domains of punctin. Because proteolytically
derived fragments of many secreted proteins have distinctive functions,
it will be interesting to investigate whether specific functions are
associated with the ~40- and ~20-kDa fragments.
A mass measurement of epitope-tagged recombinant punctin by MALDI-TOF
MS and LC-ESMS revealed that purified punctin contained multiple
species of higher than the predicted mass. Edman degradation indicated
that all these species had the same amino terminus. Further MS
analysis, glycoprotein staining, and culture in the presence of
tunicamycin A confirm that punctin contains N-linked sugars
but do not exclude the presence of O-linked sugar.
Significant alteration of mobility was not seen after peptide
N-glycosidase F treatment, suggesting that the
N-linked carbohydrate may be resistant to complete enzymatic
removal (26).
Rotary shadowing is useful for demonstrating the physical conformation
of a molecule as well as the existence of oligomeric complexes
(27-29). The data we have obtained for punctin are relevant to the
ADAMTS, lacunin, and papilin. They can be extrapolated to represent the
structure of the ancillary domains of an ADAMTS enzyme and the
"papilin cassette" (25) and provide the first insight into the
conformation of these domain assemblies. Many ECM proteins exist as
oligomers. This observation may also be the case with punctin, because
rotary shadowing electron microscopy and gel electrophoresis
occasionally suggested the presence of dimers and trimers. We
anticipate that rotary shadowing will be useful for future studies to
investigate punctin oligomerization and interactions of punctin with
putative ECM ligands.
Punctin Is an ECM Glycoprotein That Binds to the Cell Substratum in
a Spatially Specific Manner--
Nontransformed cells in culture
require a substratum for attachment, spreading, and migration. The
substratum present on an unmodified plastic tissue culture surface is
derived from the cells themselves as well as from proteins in
serum-supplemented culture medium (30-32). Quantitatively significant
components of the cell substratum are laminin, fibronectin,
vitronectin, collagen, tenascin, PG-M or versican (a
chondroitin sulfate proteoglycan), perlecan (a heparan sulfate
proteoglycan), hyaluronan, and tissue inhibitor of metalloproteases-3
(30-37). Punctin shares the subcellular distribution of molecules that
do not generally co-localize with focal contacts (e.g.
versican, hyaluronan, and tenascin) (31, 37). Because punctin is left
behind in the ECM after cell detachment with EDTA, we conclude that
when expressed in COS-1 cells, punctin binds a component of the ECM.
Punctin in culture medium may reflect an excess of more than that which
can bind to the substratum or indicate secretion from the free surface
of the cell. Punctin does not bind to ECM between the cells, indicating
that the punctin ligand is absent from these regions. Because similar
staining was seen under serum-supplemented as well as under serum-free culture conditions, it is probable that the ECM binding partner of
punctin is a molecule produced by COS-1 cells but not one derived from
fetal bovine serum.
Significance of Punctin and the ADAMTS-like Family--
Molecules
comprising ancillary domains of metalloproteases may be generated in
biological systems by proteolytic processing or through alternative
splicing of protease genes. Brooks et al. (38) found that
the proteolytically generated hemopexin domain of MMP-2 circulated in
serum and bound to the integrin v 3. This MMP-2 fragment inhibited angiogenesis by preventing membrane targeting of MMP-2 (38). So far, there are no known examples of ADAMTS-like proteins generated as splice variants of ADAMTS
genes. The discovery of punctin demonstrates for the first time the
existence of molecules closely resembling the ancillary domains of
ADAMTS that are generated as distinct gene products.
The resemblance of ADAMTSL to ADAMTS suggests a functional relationship
between these two groups of molecules. From studies on ADAMTS-1 (39)
and ADAMTS-2 (40), it is known that the ancillary domains are required
to bind and cleave substrates. ADAMTSL may offer a potential mechanism
of ADAMTS regulation via one of several possible mechanisms. As a
result of noncompetitive inhibition of ADAMTS-2, an inhibitory role has
been shown for Drosophila papilin (25). Another possibility
is that punctin may compete with ADAMTS for its substrates and protect
the substrates from cleavage. The isolated MMP-2 hemopexin domain
represents one such example. In a second example, a truncated
nonenzymatic version of ADAM-17 was shown to have a dominant negative
effect on the activation of tumor necrosis factor- (41). An
intriguing possibility is that the ADAMTS-like proteins may be
enhancers of the ADAMTS proteases. For example, the procollagen
C-proteinase enhancer protein (42) contains two domains homologous to
those found in the C-proteinase that are instrumental in binding to the
carboxyl propeptide of procollagen I and enhancing its removal (43). Very little is currently known about the regulation of ADAMTS proteases
following their activation, and it is possible that the ADAMTS-like
proteins may provide a novel general principle of regulation.
 |
ACKNOWLEDGEMENTS |
We thank C. Kassuba for editing the
manuscript, Vincent C. Hascall, Tom Tallant, Seng Hui Low, and Thomas
Weimbs for helpful discussion, members of the Apte laboratory for
critical reading of the manuscript, Satya Yadav for protein sequencing,
Monique Ross for assistance with cloning, Karen West for amino acid
analysis, and Judy Drazba for help with confocal imaging.
 |
FOOTNOTES |
*
This work was supported in part by the Cleveland Clinic
Foundation (to S. S. A.), a Yamanouchi USA Foundation Award (to
S. S. A.), and National Institutes of Health Grants EY06603 (to
J. W. C.) and HGO0734 (to M. F. S.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF176313.
§
Both authors contributed equally to this work.
§§
To whom correspondence should be addressed: Dept. of Biomedical
Engineering (ND20), Lerner Research Inst., Cleveland Clinic Foundation,
9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-3278; Fax:
216-445-4383; E-mail: aptes@bme.ri.ccf.org or
www.lerner.ccf.org/pi/apte.html.
Published, JBC Papers in Press, January 22, 2002, DOI 10.1074/jbc.M109665200
2
Approved gene symbols ADAMTSL1 and
Adamtsl1 indicate human and mouse orthologs, respectively.
The corresponding protein product of these genes, ADAMTSL-1, is
designated by the trivial name punctin because of its punctate
distribution beneath transfected cells.
3
N. Moore, B. Anand-Apte, and S. Apte,
unpublished data.
4
S. Apte, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
ECM, extracellular matrix;
ADAMTSL, a
disintegrin-like and
metalloprotease domain with
thrombospondin type I motifs like;
ADAMTS, a disintegrin-like and
metalloprotease domain with
thrombospondin type I motifs;
ADAM, a disintegrin-like and
metalloprotease;
MS, mass spectrometry;
EST, expressed
sequence tag;
LC-ESMS, liquid chromatography-electrospray mass
spectrometry;
MALDI-TOF, matrix-assisted laser desorption ionization
time-of-flight;
MMP, matrix metalloprotease;
ORF, open reading frame;
PBS, phosphate-buffered saline;
RACE, rapid amplification of cDNA
ends;
TSP, thrombospondin;
TS, thrombospondin type I domain;
HexNAc, N-acetylhexosamine;
NeuAc, N-acetylneuraminic
acid.
 |
REFERENCES |
| 1.
|
Murphy, G.,
and Knauper, V.
(1997)
Matrix Biol.
15,
511-518[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Blobel, C. P.
(1997)
Cell
90,
589-592[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Kuno, K.,
Kanada, N.,
Nakashima, E.,
Fujiki, F.,
Ichimura, F.,
and Matsushima, K.
(1997)
J. Biol. Chem.
272,
556-562[Abstract/Free Full Text]
|
| 4.
|
Hurskainen, T. L.,
Hirohata, S.,
Seldin, M. F.,
and Apte, S. S.
(1999)
J. Biol. Chem.
274,
25555-25563[Abstract/Free Full Text]
|
| 5.
|
Wallon, U. M.,
and Overall, C. M.
(1997)
J. Biol. Chem.
272,
7473-7481[Abstract/Free Full Text]
|
| 6.
|
Steffensen, B.,
Bigg, H. F.,
and Overall, C. M.
(1998)
J. Biol. Chem.
273,
20622-20628[Abstract/Free Full Text]
|
| 7.
|
Bein, K.,
and Simons, M.
(2000)
J. Biol. Chem.
275,
32167-32173[Abstract/Free Full Text]
|
| 8.
|
Bornstein, P.,
Armstrong, L. C.,
Hankenson, K. D.,
Kyriakides, T. R.,
and Yang, Z.
(2000)
Matrix Biol.
19,
557-568[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Overall, C. M.,
King, A. E.,
Sam, D. K.,
Ong, A. D.,
Lau, T. T.,
Wallon, U. M., De,
Clerck, Y. A.,
and Atherstone, J.
(1999)
J. Biol. Chem.
274,
4421-4429[Abstract/Free Full Text]
|
| 10.
|
McQuibban, G. A.,
Gong, J. H.,
Tam, E. M.,
McCulloch, C. A.,
Clark-Lewis, I.,
and Overall, C. M.
(2000)
Science
289,
1202-1206[Abstract/Free Full Text]
|
| 11.
|
Zhang, X. P.,
Kamata, T.,
Yokoyama, K.,
Puzon-McLaughlin, W.,
and Takada, Y.
(1998)
J. Biol. Chem.
273,
7345-7350[Abstract/Free Full Text]
|
| 12.
|
Zolkiewska, A.
(1999)
Exp. Cell Res.
252,
423-431[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Kuno, K.,
and Matsushima, K.
(1998)
J. Biol. Chem.
273,
13912-13917[Abstract/Free Full Text]
|
| 14.
|
Georgiadis, K. E.,
Hirohata, S.,
Seldin, M. F.,
and Apte, S. S.
(1999)
Genomics
62,
312-315[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Watson, M. L.,
and Seldin, M. F.
(1994)
Methods Mol. Genet.
5,
369-387
|
| 16.
|
Crabb, J. W.,
West, K. A.,
Dodson, W. S.,
and Hulmes, J. D.
(1997)
in
Current Protocols in Protein Science
(Coligan, J. E.
, Ploegh, H. L.
, Smith, J. A.
, and Speicher, D. W., eds)
, pp. 11.9.1-11.9.42, John Wiley & Sons, Inc., New York
|
| 17.
|
Kapron, J. T.,
Hilliard, G. M.,
Lakins, J. N.,
Tenniswood, M. P.,
West, K. A.,
Carr, S. A.,
and Crabb, J. W.
(1997)
Protein Sci.
6,
2120-2133[Medline]
[Order article via Infotrieve]
|
| 18.
|
Crabb, J. W.,
Nie, Z.,
Chen, Y.,
Hulmes, J. D.,
West, K. A.,
Kapron, J. T.,
Ruuska, S. E.,
Noy, N.,
and Saari, J. C.
(1998)
J. Biol. Chem.
273,
20712-20720[Abstract/Free Full Text]
|
| 19.
|
Sakai, L. Y.,
and Keene, D. R.
(1994)
Methods Enzymol.
245,
29-52[Medline]
[Order article via Infotrieve]
|
| 20.
|
Kozak, M.
(1989)
J. Cell Biol.
108,
229-241[Abstract/Free Full Text]
|
| 21.
|
Gavel, Y.,
and von Heijne, G.
(1990)
Protein Eng.
3,
433-442[Abstract/Free Full Text]
|
| 22.
|
Bornstein, P.,
and Sage, E. H.
(1994)
Methods Enzymol.
245,
62-85[Medline]
[Order article via Infotrieve]
|
| 23.
|
Nagase, T.,
Ishikawa, K.,
Miyajima, N.,
Tanaka, A.,
Kotani, H.,
Nomura, N.,
and Ohara, O.
(1998)
DNA Res.
5,
31-39[Abstract]
|
| 24.
|
Nardi, J. B.,
Martos, R.,
Walden, K. K.,
Lampe, D. J.,
and Robertson, H. M.
(1999)
Insect Biochem. Mol. Biol.
29,
883-897[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Kramerova, I. A.,
Kawaguchi, N.,
Fessler, L. I.,
Nelson, R. E.,
Chen, Y.,
Kramerov, A. A.,
Kusche-Gullberg, M.,
Kramer, J. M.,
Ackley, B. D.,
Sieron, A. L.,
Prockop, D. J.,
and Fessler, J. H.
(2000)
Development
127,
5475-5485[Abstract]
|
| 26.
|
Tretter, V.,
Altmann, F.,
and Marz, L.
(1991)
Eur. J. Biochem.
199,
647-652[Medline]
[Order article via Infotrieve]
|
| 27.
|
Holden, P.,
Meadows, R. S.,
Chapman, K. L.,
Grant, M. E.,
Kadler, K. E.,
and Briggs, M. D.
(2001)
J. Biol. Chem.
276,
6046-6055[Abstract/Free Full Text]
|
| 28.
|
Maddox, B. K.,
Sakai, L. Y.,
Keene, D. R.,
and Glanville, R. W.
(1989)
J. Biol. Chem.
264,
21381-21385[Abstract/Free Full Text]
|
| 29.
|
Olin, A. I.,
Morgelin, M.,
Sasaki, T.,
Timpl, R.,
Heinegard, D.,
and Aspberg, A.
(2001)
J. Biol. Chem.
276,
1253-1261[Abstract/Free Full Text]
|
| 30.
|
Hayman, E. G.,
Oldberg, A.,
Martin, G. R.,
and Ruoslahti, E.
(1982)
J. Cell Biol.
94,
28-35[Abstract/Free Full Text]
|
| 31.
|
Hayman, E. G.,
Pierschbacher, M. D.,
Suzuki, S.,
and Ruoslahti, E.
(1985)
Exp. Cell Res.
160,
245-258[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Ohji, M.,
Sundar Raj, N.,
Hassell, J. R.,
and Thoft, R. A.
(1994)
Invest. Ophthalmol. Visual Sci.
35,
479-485[Abstract/Free Full Text]
|
| 33.
|
Snow, A. D.,
Sekiguchi, R.,
Nochlin, D.,
Fraser, P.,
Kimata, K.,
Mizutani, A.,
Arai, M.,
Schreier, W. A.,
and Morgan, D. G.
(1994)
Neuron
12,
219-234[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Singer, I. I., II,
Scott, S.,
Kawka, D. W.,
and Hassell, J. R.
(1987)
Exp. Cell Res.
173,
558-571[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Isogai, Z.,
Shinomura, T.,
Yamakawa, N.,
Takeuchi, J.,
Tsuji, T.,
Heinegard, D.,
and Kimata, K.
(1996)
Cancer Res.
56,
3902-3908[Abstract/Free Full Text]
|
| 36.
|
Staskus, P. W.,
Masiarz, F. R.,
Pallanck, L. J.,
and Hawkes, S. P.
(1991)
J. Biol. Chem.
266,
449-454[Abstract/Free Full Text]
|
| 37.
|
Yamagata, M.,
Saga, S.,
Kato, M.,
Bernfield, M.,
and Kimata, K.
(1993)
J. Cell Sci.
106,
55-65[Abstract]
|
| 38.
|
Brooks, P. C.,
Silletti, S.,
von Schalscha, T. L.,
Friedlander, M.,
and Cheresh, D. A.
(1998)
Cell
92,
391-400[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Kuno, K.,
Terashima, Y.,
and Matsushima, K.
(1999)
J. Biol. Chem.
274,
18821-18826[Abstract/Free Full Text]
|
| 40.
|
Colige, A.,
Sieron, A. L., Li, S. W.,
Schwarze, U.,
Petty, E.,
Wertelecki, W.,
Wilcox, W.,
Krakow, D.,
Cohn, D. H.,
Reardon, W.,
Byers, P. H.,
Lapiere, C. M.,
Prockop, D. J.,
and Nusgens, B. V.
(1999)
Am. J. Hum. Genet.
65,
308-317[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Solomon, K. A.,
Pesti, N., Wu, G.,
and Newton, R. C.
(1999)
J. Immunol.
163,
4105-4108[Abstract/Free Full Text]
|
| 42.
|
Takahara, K.,
Kessler, E.,
Biniaminov, L.,
Brusel, M.,
Eddy, R. L.,
Jani-Sait, S.,
Shows, T. B.,
and Greenspan, D. S.
(1994)
J. Biol. Chem.
269,
26280-26285[Abstract/Free Full Text]
|
| 43.
|
Hulmes, D. J.,
Mould, A. P.,
and Kessler, E.
(1997)
Matrix Biol.
16,
41-45[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
O. F. Hatipoglu, S. Hirohata, M. Z. Cilek, H. Ogawa, T. Miyoshi, M. Obika, K. Demircan, R. Shinohata, S. Kusachi, and Y. Ninomiya
ADAMTS1 Is a Unique Hypoxic Early Response Gene Expressed by Endothelial Cells
J. Biol. Chem.,
June 12, 2009;
284(24):
16325 - 16333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. W. Wang, M. Dlugosz, R. P. T. Somerville, M. Raed, R. S. Haltiwanger, and S. S. Apte
O-Fucosylation of Thrombospondin Type 1 Repeats in ADAMTS-like-1/Punctin-1 Regulates Secretion: IMPLICATIONS FOR THE ADAMTS SUPERFAMILY
J. Biol. Chem.,
June 8, 2007;
282(23):
17024 - 17031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Miyoshi, S. Hirohata, H. Ogawa, M. Doi, M. Obika, T. Yonezawa, Y. Sado, S. Kusachi, S. Kyo, S. Kondo, et al.
Tumor-specific expression of the RGD-{alpha}3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice
FASEB J,
September 1, 2006;
20(11):
1904 - 1906.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sezaki, S. Hirohata, A. Iwabu, K. Nakamura, K. Toeda, T. Miyoshi, H. Yamawaki, K. Demircan, S. Kusachi, Y. Shiratori, et al.
Thrombospondin-1 Is Induced in Rat Myocardial Infarction and Its Induction Is Accelerated by Ischemia/Reperfusion
Experimental Biology and Medicine,
October 1, 2005;
230(9):
621 - 630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. N. Wight
The ADAMTS Proteases, Extracellular Matrix, and Vascular Disease: Waking the Sleeping Giant(s)!
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2005;
25(1):
12 - 14.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nakamura, S. Hirohata, T. Murakami, T. Miyoshi, K. Demircan, T. Oohashi, H. Ogawa, K. Koten, K. Toeda, S. Kusachi, et al.
Dynamic Induction of ADAMTS1 Gene in the Early Phase of Acute Myocardial Infarction
J. Biochem.,
October 1, 2004;
136(4):
439 - 446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Llamazares, S. Cal, V. Quesada, and C. Lopez-Otin
Identification and Characterization of ADAMTS-20 Defines a Novel Subfamily of Metalloproteinases-Disintegrins with Multiple Thrombospondin-1 Repeats and a Unique GON Domain
J. Biol. Chem.,
April 4, 2003;
278(15):
13382 - 13389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Wu, Y. Yang, N. Shaw, S. Bhattacharya, L. Yan, K. West, K. Roth, N. Noy, J. Qin, and J. W. Crabb
Mapping the Ligand Binding Pocket in the Cellular Retinaldehyde Binding Protein
J. Biol. Chem.,
March 28, 2003;
278(14):
12390 - 12396.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|